Status:
COMPLETED
Irbesartan and Atenolol in Hypertensive Heart Disease
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Bristol-Myers Squibb
Sanofi
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the im...
Detailed Description
We included 115 patients with hypertension and cardiac hypertrophy, established by echocardiography. Extensive echocardiographic examinations, ultrasonography of the carotid arteries, 24h Holter regis...
Eligibility Criteria
Inclusion
- At least 18 ys old
- Male or female with no child bearing potential
- Seated blood pressure diastolic 90-115 mm Hg
- Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women
- Informed consent
Exclusion
- Coronary artery disease, heart failure or other significant cardiac disorder
- Cerebrovascular accident within the past 6 months
- A seated systolic blood pressure above 200 mm Hg
- Significant renal disease, collagen or vascular disease, or gastrointestinal condition
- Significant allergy or intolerance to study drug
- Alcohol or drug abuse
- Uncontrolled diabetes mellitus
Key Trial Info
Start Date :
April 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 1997
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00389168
Start Date
April 1 1995
End Date
April 1 1997
Last Update
May 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory
Stockholm, Sweden, SE-182 88